Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 14/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.55 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929784 | 0.93 | CSF1R (0.62) | CSF1RPDE4B | |
| SCHEMBL5929770 | 0.92 | CSF1R (0.63) | CSF1RPDE4BNUDT1 | |
| SCHEMBL5929776 | 0.90 | CSF1R (0.61) | CSF1RPDE4BNUDT1 | |
| SCHEMBL5929828 | 0.90 | CSF1R (0.59) | CSF1RPDE4B | |
| SCHEMBL5929791 | 0.88 | CSF1R (0.63) | CSF1RPDE4BNUDT1 | |
| SCHEMBL5929844 | 0.88 | CSF1R (0.57) | CSF1RPDE4B | |
| SCHEMBL5929813 | 0.87 | CSF1R (0.83) | CSF1RNUDT1 | |
| SCHEMBL5929633 | 0.86 | CSF1R (0.75) | CSF1RPDE4B | |
| SCHEMBL5929807 | 0.84 | CSF1R (0.64) | CSF1RPDE4BNUDT1 | |
| SCHEMBL5929664 | 0.84 | CSF1R (0.62) | CSF1RPDE4BNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | claimed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | claimed |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | CSF1R 637/4885PDE4B 768/4885NUDT1 3959/4885 |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | CSF1R 889/4885PDE4B 870/4885NUDT1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.